Technetium-99m MIBI single photon emission computed tomography as an indicator of prognosis for patients with lung cancer —Preliminaly report—

Komori, Tsuyoshi; Narabayashi, Isamu; Matsui, Ritsuo; Sueyoshi, Kozo; Aratani, Taizo; Utsunomiya, Keita

doi:10.1007/bf02988286

Cited by 8 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple small studies have evaluated imaging with 99m Tc-sestamibi, or a similar agent tetrafosmin, as a surrogate for chemotherapy in patients with lung cancer, finding that imaging uptake was highly associated with paclitaxel-based chemotherapy response (Ceriani et al, 1997; Fuster et al, 2003; Komori et al, 2000; Mohan and Miles, 2009; Nishiyama et al, 2000; Shih et al, 2003; Yuksel et al, 2002). A meta-analysis concluded the test had predictive value for this purpose (Mohan and Miles, 2009).…”

Section: Imaging Drug Uptake and Accumulation In Tissues And In Tumentioning

confidence: 99%

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

Amiri‐Kordestani

Basseville

Kurdziel

et al. 2012

Drug Resistance Updates

199

128

View full text Add to dashboard Cite

This special issue of Drug Resistance Updates is dedicated to multidrug resistance protein 1 (MDR-1), 35 years after its discovery. While enormous progress has been made and our understanding of drug resistance has become more sophisticated and nuanced, after 35 years the role of MDR-1 in clinical oncology remains a work in progress. Despite clear in vitro evidence that P-glycoprotein (Pgp), encoded by MDR-1, is able to dramatically reduce drug concentrations in cultured cells, and that drug accumulation can be increased by small molecule inhibitors, clinical trials testing this paradigm have mostly failed. Some have argued that it is no longer worthy of study. However, repeated analyses have demonstrated MDR-1 expression in a tumor is a poor prognostic indicator leading some to conclude MDR-1 is a marker of a more aggressive phenotype, rather than a mechanism of drug resistance. In this review we will re-evaluate the MDR-1 story in light of our new understanding of molecular targeted therapy, using breast and lung cancer as examples. In the end we will reconcile the data available and the knowledge gained in support of a thesis that we understand far more than we realize, and that we can use this knowledge to improve future therapies.

show abstract

Section: Imaging Drug Uptake and Accumulation In Tissues And In Tumentioning

confidence: 99%

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

Amiri‐Kordestani

Basseville

Kurdziel

et al. 2012

Drug Resistance Updates

199

128

View full text Add to dashboard Cite

show abstract

Residual tumor uptake of [^99mTc]‐sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival

Dunnwald

Gralow

Ellis

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUND Studies utilizing serial [99mTc]‐sestamibi (MIBI) scintimammography have reported accurate prediction of tumor response in patients with locally advanced breast carcinoma (LABC) undergoing neoadjuvant chemotherapy. The pathologic response of LABC to presurgical treatment regimens is a prognostic indicator of survival. The authors tested whether MIBI uptake posttherapy predicted survival. METHODS Sixty‐two patients with LABC underwent MIBI scintimammography just before chemotherapy and 2 months after treatment initiation. An additional MIBI scan was performed if treatment lasted > 3 months. The affected breast was imaged within 10 minutes after injection to reflect early uptake, which the authors have shown to be related to tumor blood flow. MIBI uptake was quantified using the lesion‐to‐normal breast (L:N) ratio. Most patients (93%) received weekly dose‐intensive doxorubicin‐based treatment. Disease‐free survival (DFS) and overall survival (OS) were compared with posttherapy primary MIBI uptake and with other established prognostic factors for neoadjuvantly treated LABC, namely, primary tumor pathologic response and posttherapy axillary lymph node status. RESULTS Patients with high uptake on the last observed MIBI scan (i.e., the L:N ratio was greater than the median value) had poorer DFS and OS (P < 0.01 and P = 0.01, respectively). Residual MIBI uptake retained independent prognostic significance in preliminary multivariate analysis that included other established prognostic markers. CONCLUSIONS High primary breast tumor MIBI uptake after neoadjuvant chemotherapy predicted poor survival, suggesting serial MIBI imaging may provide a useful quantitative surrogate end point for neoadjuvant chemotherapy trials. Given the association between MIBI uptake and tumor blood flow, this prognostic capability may be related to retained tumor vascularity after treatment. Cancer 2005. © 2005 American Cancer Society.

show abstract

Tc-99m MIBI SPECT in prediction of prognosis in patients with small cell lung cancer

et al. 2006

View full text Add to dashboard Cite

show abstract

Technetium-99m MIBI single photon emission computed tomography as an indicator of prognosis for patients with lung cancer —Preliminaly report—

Abstract: These results suggest that RI is the most useful among Tc-99m MIBI indices of primary lung cancer in predicting prognosis.

Cited by 8 publications

References 13 publications

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

Residual tumor uptake of [^99mTc]‐sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival

Tc-99m MIBI SPECT in prediction of prognosis in patients with small cell lung cancer

Contact Info

Product

Resources

About

Technetium-99m MIBI single photon emission computed tomography as an indicator of prognosis for patients with lung cancer —Preliminaly report—

Abstract: These results suggest that RI is the most useful among Tc-99m MIBI indices of primary lung cancer in predicting prognosis.

Cited by 8 publications

References 13 publications

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies

Residual tumor uptake of [99mTc]‐sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival

Tc-99m MIBI SPECT in prediction of prognosis in patients with small cell lung cancer

Contact Info

Product

Resources

About

Residual tumor uptake of [^99mTc]‐sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival